Christian Vareika, P.C.

Prior to joining Kirkland, Christian was involved in the following matters:

GP-led Continuation Vehicle Transactions

• Three-lead buyer syndicate in a $2.2 billion multi-asset continuation fund transaction.
• Co-lead buyer in a $2.3 billion multi-asset continuation fund transaction.
• Sovereign wealth fund as lead buyer in a $3 billion single-asset recapitalization of a data center business.
• Co-lead buyer in a €2.3 billion multi-asset continuation fund transaction.
• Co-lead buyer in a €2.5 billion multi-asset continuation fund transaction.
• Lead buyers in the $2.75 billion recapitalization of private equity and mezzanine funds.
• Lead buyer in a $1.5 billion multi-asset continuation fund transaction.
• Lead buyers in a $1.3 billion multi-asset continuation fund transaction.
• Lead buyer in a $1.2 billion multi-asset continuation fund transaction.
• Lead buyer in a $830 million single-asset continuation fund transaction.
• European secondary buyer as lead buyer with respect to a $1+ billion acquisition of a portfolio of more than 200 credit and REIT positions from a global insurance company and eight of its client accounts into a continuation fund, as well as the launch of a new credit fund platform, including the warehousing of that fund’s initial portfolio.
• Lead buyer in a $360 million multi-asset continuation fund transaction.
• Lead buyers in the $270 million recapitalization of two Chinese private equity funds.

Other Transactions

• Secondary buyer in its purchase of a $1.3 billion portfolio of 90+ fund interests from an Asian insurance company.
• Australian sovereign wealth fund on the restructuring of its global venture capital portfolio and an unwinding of related fund structures in a $1.5 billion transaction.
• Healthcare-focused manager on formation, fundraise and launch of $2 billion closed-end fund.
• Biotech investment firm on formation of biotech impact investment fund.
• Private equity sponsor in its investment in integrated healthcare provider.
• Private equity sponsor in ongoing portfolio company matters, including corporate governance and general corporate matters.